(NASDAQ: LYEL) Lyell Immunopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.78%.
Lyell Immunopharma's earnings in 2026 is -$248,477,000.On average, 11 Wall Street analysts forecast LYEL's earnings for 2026 to be -$181,825,696, with the lowest LYEL earnings forecast at -$183,715,042, and the highest LYEL earnings forecast at -$171,621,755. On average, 11 Wall Street analysts forecast LYEL's earnings for 2027 to be -$192,546,695, with the lowest LYEL earnings forecast at -$234,386,773, and the highest LYEL earnings forecast at -$134,569,982.
In 2028, LYEL is forecast to generate -$162,268,143 in earnings, with the lowest earnings forecast at -$189,238,501 and the highest earnings forecast at -$137,143,022.